About UCSF Search UCSF UCSF Medical Center

Lisa Anne Bero, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
bero_lisa

Professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, UCSF

bero@medicine.ucsf.edu

Phone: (415) 476-1067 (voice)
Box 0613, UCSF

View on UCSF Profiles


Education

Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)


Professional Experience

  • 1988-1992
    Pew Fellowship, Institute for Health Policy Studies, UCSF
  • 1994-present
    Co-Director, San Francisco Cochrane Center
  • 6/00-present
    Vice Chair, Department of Clinical Pharmacy, UCSF
  • 6/01-present
    Professor, Dept. Clinical Pharmacy/ Institute for Health Policy Studies/ Center for Tobacco Control Research and Education, UCSF

Honors & Awards

  • 1994-1992
    Special Consultant to the European Union Committee on Technology Assessment
  • 1992
    Best article published in 1996 in the Intl J Technology Assessment in Health Care
  • 1992
    Special consultant to the World Bank for a background paper on Tobacco Control Policies
  • 2000-2001, 2002
    Special Advisor to World Health Organization

Selected Publications

  1. Tovey D, Churchill R, Bero L. Evidence based medicine: looking forward and building on what we have learnt. BMJ. 2014; 349:g4508.
    View on PubMed
  2. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014; 4:MR000034.
    View on PubMed
  3. Coralic Z, Kanzaria HK, Bero L, Stein J. Staff Perceptions of an On-site Clinical Pharmacist Program in an Academic Emergency Department after One Year. West J Emerg Med. 2014 Mar; 15(2):205-10.
    View on PubMed
  4. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria: krauth et Al. Respond. Environ Health Perspect. 2014 Mar 1; 122(3):A67.
    View on PubMed
  5. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
    View on PubMed
  6. Alexander PE, Bero L, Montori VM, Brito JP, Stoltzfus R, Djulbegovic B, Neumann I, Rave S, Guyatt G. World Health Organization recommendations are often strong based on low confidence in effect estimates. J Clin Epidemiol. 2014 Jun; 67(6):629-34.
    View on PubMed
  7. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev. 2013; 12:ED000075.
    View on PubMed
  8. Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med. 2013 Dec 9; 173(22):2032-6.
    View on PubMed
  9. Chahal HS, St Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health. 2013 Dec; 3(2):20405.
    View on PubMed
  10. Grundy Q, Bero L, Malone R. Interactions between Non-Physician Clinicians and Industry: A Systematic Review. PLoS Med. 2013 Nov; 10(11):e1001561.
    View on PubMed
  11. Apollonio DE, Glantz SA, Bero LA. Term limits and the tobacco industry. Soc Sci Med. 2014 Mar; 104:1-5.
    View on PubMed
  12. Moynihan RN, Cooke GP, Doust JA, Bero L, Hill S, Glasziou PP. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 2013 Aug; 10(8):e1001500.
    View on PubMed
  13. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect. 2013 Sep; 121(9):985-92.
    View on PubMed
  14. Wolfe N, Gøtzsche PC, Bero L. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev. 2013; 2:31.
    View on PubMed
  15. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ. 2013; 346:f2231.
    View on PubMed
  16. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013 Apr 8; 173(7):580-1.
    View on PubMed
  17. Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43.
    View on PubMed
  18. Conway J, Bero L, Ondari C, Wasan KM. Review of the quality of pediatric medications in developing countries. J Pharm Sci. 2013 May; 102(5):1419-33.
    View on PubMed
  19. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013; 2:CD010398.
    View on PubMed
  20. Odierna DH, Forsyth SR, White J, Bero LA. The cycle of bias in health research: a framework and toolbox for critical appraisal training. Account Res. 2013; 20(2):127-41.
    View on PubMed

Go to UCSF Profiles, powered by CTSI